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Introduction: In patients with oncogene-addicted NSCLC
and isolated central nervous system progression (iCNS),
tissue biopsy is challenging, and the clinical utility of plasma
liquid biopsy (i.e., circulating tumor DNA [ctDNA]) is
unknown.
Methods: Patients with advanced NSCLC with known
baseline genomic alteration (GA) (EGFR, ALK, BRAF, KRAS,
HER2, ROS1, MET, PIK3CA, STK11, TP53) on tissue were
divided into three groups on the basis of their disease
progression pattern: iCNS, extra-CNS only (noCNS), or both
(cCNS). All patients with available plasma ctDNA were
included and were analyzed by next-generation sequencing
InVisionFirst-Lung. ctDNA was considered positive if at
least one GA was detected. Cell-free tumor DNA was
analyzed in cerebrospinal fluid when available.
Results: Out of 517 patients screened, 247 were included:
54 had iCNS, 99 had noCNS, and 94 had cCNS progressive
disease (64, 128, and 110 ctDNA samples, respectively).
CtDNA was positive in 52% iCNS versus 84% in noCNS and
92% in cCNS (p < 0.00001), with lower detection of driver
(37% versus 77% and 73%, respectively) and resistance
alterations (6% versus 45% and 44%). Patients with iCNS
and positive ctDNA were more at risk of extra-CNS pro-
gression (32% versus 7%, p ¼ 0.026). In 12 patients with
iCNS, ctDNA was positive in six (50%) plasma and in 10
(83%) paired cerebrospinal fluid (p ¼ 0.193).
Conclusions: Although tagged amplicon-based next-
generation sequencing has high detection rates of GA in
plasma ctDNA in patients with NSCLC with extra-CNS
disease, detection rate of GAs (52%) is lower in the sub-
set of patients with iCNS disease. Complementary tests
such as cerebrospinal fluid cell-free DNA may be useful.
Further evidence would be beneficial to understand the
genomic landscape in patients with NSCLC and iCNS.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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LeptomeningealIntroduction
Central nervous system (CNS) metastases are
frequently found in oncogene-addicted NSCLC, with
percentages reaching up to 50% for brain and 10% for
leptomeningeal metastases.1-3 Especially in patients
treated with first-generation tyrosine kinase inhibitors
(TKIs), isolated CNS progression (iCNS) is common,
potentially because of the blood-brain and blood-tumor
barriers.4 If the planned treatment is to change the
TKI, subsequent TKIs are preferentially selected on the
basis of the resistance mechanism to the current TKI.
Although genomic profiling on tissue is considered
the standard procedure, analysis fails in up to 25% of the
cases.5 One potential alternative source of tumor DNA
can be identified from plasma. Circulating tumor DNA
(ctDNA), also referred to as “liquid biopsy” has emerged
as an ideal minimally invasive tool, especially in the case
of hard-to-biopsy lesions or insufficient tissue mate-
rial.6,7 It is well established that oncogenic drivers and
resistance mutations are detected in ctDNA with high
sensitivity and specificity.6,8
In the case of iCNS, physiological and/or pathologic
factors such as blood-tumor barrier could reduce the
presence of ctDNA in the bloodstream and subsequently
reduce the accuracy of liquid biopsy for genomic alter-
ation (GA) detection. This is supported by several studies
in patients with primary brain tumors or CNS-restricted
metastases.3,9-11 However, the current evidence is
limited in the absence of large series performed with
adequate and highly sensitive genomic assays, in
particular in patients with oncogene-addicted NSCLC. In
this study, we aimed to assess the clinical utility of liquid
biopsy through detection of GA in plasma ctDNA from
patients with oncogene-addicted NSCLC and isolated
CNS progression.
Materials and Methods
Patients and Samples
Patients with NSCLC were prospectively enrolled in a
study evaluating liquid biopsy (NCT02666612) from
January 2016 to November 2018 at Gustave Roussy.
March 2020 ctDNA in NSCLC with isolated CNS progression 385Cases were selected for our study on the basis of the
following inclusion criteria: (1) stage IV disease; (2)
known tissue GA at baseline in EGFR, ALK, BRAF, KRAS,
HER2, ROS1, MET, PIK3CA, STK11, or TP53; and (3) at
least one liquid biopsy collected at baseline or at the
time of disease progression and successfully analyzed by
next-generation sequencing (NGS) with InVisionFirst-
Lung assay.
Eligible patients were stratified in three groups: (1)
iCNS: isolated CNS progression while stable or no extra-
CNS disease; (2) noCNS: extra-CNS progression and no
CNS involvement; and (3) cCNS: CNS involvement and
extra-CNS progression (Table 1).
Radiologic assessment consisted of at least one extra-
CNS and one CNS imaging method (body computed to-
mography [CT] scan or positron emission tomography-CT
scan, and brain magnetic resonance imaging [MRI), brain
CT scan, and/or spinal MRI). Leptomeningeal disease was
diagnosed by cerebrospinal fluid (CSF) cytology or a com-
bination of compatible clinical symptoms and typical MRI
findings.12 Disease progression was assessed per in-
vestigator’s criteria. For leptomeningeal involvement, a
neurologic aggravation was considered as clinical
progression.
Liquid biopsy was performed at baseline and/or at
disease progression, within 1 month of the radiologic
assessment, resulting in serial plasma ctDNA results for
a limited number of patients. CSF were collected when
available.
Clinical, pathologic, molecular, and imaging data were
retrospectively collected.
Genomic Profiling of ctDNA
Blood (10–20 mL) was collected in ethyl-
enediaminetetraacetic acid or Cell-Free DNA BCT STRECK
tubes. Plasma was isolated using a standard operating
procedure, and ctDNA analysis was centralized (Inivata,
Cambridge, UK, and Research Triangle Park, Durham, NC)
using InVisionFirst-Lung, a tagged amplicon-based NGS
comprehensive genomic profiling assay that identifies sin-
gle nucleotide variants, insertions and deletions, copy
number variations, and fusions (variant 1 to 3 of EML4-ALK
fusions and CD74-, SLC34A2-, SDC4-, and EZR-ROS1) with
whole gene and gene hotspots across a 36-gene panel
(Supplementary Fig. 1); methods were previously
described.8,13,14Table 1. Patients’ Stratification According to Their Disease
Evolution Pattern
Groups CNS Progression Extra-CNS Progression
iCNS D -
noCNS - D
cCNSa D D
astable CNS disease was also allowed in cCNS group.CSF ctDNA was performed from 2 mL of CSF. Samples
were analyzed by direct sequencing (EGFR exon 19, 20,
21, 18) or NGS (Sentosa NSCLC Panel, Vela Diagnostics,
Singapore) at Gustave Roussy.Outcomes
The primary objective of the study was to determine the
proportion of patients with positive ctDNA, defined as the
identification of at least one somatic GA of known patho-
genicity, irrespective of its mutant allele fraction (MAF%).
Identified GAs were categorized under the following:
actionable drivers (EGFR exon 19, 21, 18 and exon 20
insertion, BRAF, HER2 exon 20 insertion, MET exon 14
skipping mutations, ALK and ROS1 rearrangements),
resistance alterations (EGFR T790M, EGFR C797S/G,
EGFR G729S/V, EGFR L747P, ALK mutations, MET
D1246N, EGFR, MET and HER2 amplifications), or other
GA (e.g., KRAS/NRAS/HRAS, MAPK, TP53, STK11,
PIK3CA). GAs were considered actionable if treatment
options were available within an FDA/EMA approval or
ongoing clinical trials at our institution.
For positive plasma ctDNA, comparisons among MAF
% in the different groups were performed. When more
than one GA was detected per sample, the highest MAF%
was selected for analysis.
For the iCNS group, the occurrence of an extra-CNS
progression and the subsequent development of a CNS
progression were evaluated. Extra-CNS progression-free
survival (PFS) and CNS PFS were calculated and compared
between patients with negative and positive iCNS ctDNA.Statistical Analysis
Statistical analyses were performed using R-Studio
version 3.5.2 and IBM SPSS Statistics 20. Median (inter-
quartile-range) values and proportions (percentage) were
provided for the description of continuous and categorical
variables, respectively. Mean and proportions were
compared using t test (or ANOVA if appropriate) and chi-
square test (or Fisher’s exact test, if appropriate),
respectively.
The association between clinical or molecular vari-
ables and ctDNA positivity was explored with a logistic
regression. First, a univariate analysis was performed.
All variables reaching a p value less than 0.1 were
included in a multivariable. Any p value less than 0.05
was considered statistically significant.
Extra-CNS PFS and CNS PFS were defined as the
time between the date of ctDNA collection and extra-
CNS and CNS disease progression, respectively. Me-
dian PFS was estimated with the Kaplan-Meier method
and compared with the log-rank test. The median
follow-up was calculated with the reverse Kaplan-
Meier method.
NSCLC pts with ≥ 1 plasma ctDNA
n = 517
Pts with ≥ 1 plasma ctDNA 
by InVisionFirst-Lung
n = 364
ctDNA collected at baseline/PD
n = 247 pts
(302 samples)
    No known tissue/baseline GA: n = 44
    Lost to FU: n = 41 
    ctDNA at SD/PR/CR: n = 13    
    Non-metastatic disease: n = 12
    Other synchronous cancer: n = 4
    Failed ctDNA: n = 3
iCNS
n = 54 pts
(64 samples)
noCNS
n = 99 pts
(128 samples)
cCNS
n = 94 pts
(110 samples)
    Not sent for InVisionFirst-Lung assay 
    (PCR, other NGS panels):
              n = 153 
Excluded pts: 
Figure 1. Flowchart of the study population. CR, complete response; ctDNA, circulating tumor DNA (liquid biopsy); GA,
genomic alterations; FU, follow-up; n, number; NGS, next-generation sequencing; PCR, polymerase chain reaction; PD,
progressive disease; PR, partial response; Pts, patients; SD, stable disease.
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Patient Selection and Characteristics
Between January 2016 and June 2018, 517 patients
with NSCLC had at least one plasma ctDNA extracted,Table 2. Patients Characteristics
Characteristics iCNS (n ¼ 54 pts)
Age at first-line treatment —
Median (y), range (min, max) 59 (23–83)
Sex —
Male 14 (26%)
Female 40 (74%)
History of smoking —
Never/light smoker (<15 PY) 41 (76%)
Smoker more or equal to 15 PY 13 (24%)
Histology —
Adenocarcinoma 53 (98%)
Squamous carcinoma 0
Other 1 (2%)
GA at baseline tissue biopsies —
EGFR mutation exon 19, 21, 18 28 (51%)
exon 20 insertions 0
ALK fusion 17 (31%)
BRAF V600E mutation 2 (4%)
KRAS mutation 3 (6%)
ROS1 fusion 2 (4%)
HER2 mutation 1 (2%)
MET mutation 0
PIK3CA mutation 1 (2%)
Other (TP53 only, STK11) 0
Number of metastatic sites at baseline —
Median, range 1 (1-5)
CNS involvement at baseline, yes 38 (70%)
CNS, central nervous system; GA, genomic alterations; NA; not applicable; pts,and 247 had an InVisionFirst-Lung analysis collected at
baseline or at disease progression. A total of 302 plasma
samples were available (Fig. 1 – Flowchart), 54 patients
had iCNS (64 samples), 99 had noCNS (128 samples),noCNS (n ¼ 99 pts) cCNS (n ¼ 94 pts) p Value
— — 0.001
65 (23–89) 59 (26–75) —
— — 0.072
40 (40%) 42 (45%) —
59 (60%) 52 (55%) —
— — 0.694
67 (68%) 64 (68%) —
28 (28%) 28 (30%) —
— — 0.151
89 (90%) 88 (94%) —
3 (3%) 2 (2%) —
7 (7%) 4 (4%) —
— — —
38 (38%) 43 (46%)
4 (4%) 2 (2%) —
8 (8%) 12 (13%) —
15 (15%) 8 (9%) —
17 (17%) 11 (12%) —
4 (4%) 4 (4%) —
3 (3%) 7 (7%) —
2 (2%) 2 (2%) —
3 (3%) 1 (1%) —
5 (5%) 4 (4%) —
— — 0.005
2 (1-6) 2 (1-6) —
NA 66 (70%) 0.983
patients; PY, pack-year; y, years.
March 2020 ctDNA in NSCLC with isolated CNS progression 387and 94 had cCNS (110 samples). Patients’ and samples’
characteristics are depicted in Table 2 and
Supplementary Table 1.
The iCNS group included 22 patients with CNS-
restricted metastases and 32 patients with isolated
CNS progression. Leptomeningeal involvement was more
common in the iCNS group compared with the cCNS
group (36% versus 10%, p < 0.0001). The patients with
CNS metastases (iCNS and cCNS groups) were younger,
were more likely to have ALKþ adenocarcinoma, and
had in 70% of the cases the CNS lesions present at
diagnosis (Table 2). Patients with systemic progression
had more metastatic sites at diagnosis of advanced dis-
ease (2 versus 1) and at the moment of sample collection
(3 versus 2), and more failure sites (2 versus 1) (p <
0.001, Supplementary Table 1).
The genomic landscape of the overall populations
included 46% EGFR mutations, 15% ALK fusions, 13%
KRAS, 10% BRAF, 4% HER2 alterations, 4% ROS1 fu-
sions, and in smaller percentages, MET alterations,
PI3KCA, STK11, and TP53 mutations (Table 2). Di-
versity of GA in the systemic progression group was
higher than that in the iCNS group, with a higher
prevalence of ALK rearrangements in iCNS than in
noCNS/cCNS (31% versus 8% versus 13%, p < 0.01)
(Fig. 2).
iCNS progression was observed in 72% after first-
generation TKI, in 23% after second-generation TKI,
and in 5% after third-generation TKI (Supplementary
Table 1).Plasma ctDNA Positivity and CNS Invasion
Plasma ctDNA was positive in 52% in iCNS versus
84% in noCNS and 92% in cCNS (p < 0.00001) (Fig. 3,
Table 3).
In iCNS compared with noCNS/cCNS, the perfor-
mance of ctDNA analysis was lower for the detection of
drivers (p < 0.00001), resistance mutation (p ¼51%
31%
4%
2%
6%
4%2%
42%
8%
17%
3%
4%
5%
3%
2%
iCNS noCNS
Figure 2. Distribution of GAs at tissue0.00001), and for other GAs (p < 0.00001). In line with
these results, the detection of EGFR T790M resistance
mutation was also significantly lower in patients with
progressive iCNS compared with other groups (p ¼
0.0002) (Table 3). There was a slight tendency of the
occurrence of more comutations across cCNS/noCNS
(75%) compared with iCNS (61%), however without
reaching statistical significance (p ¼ 0.09).
Serial samples were available for 18 patients in the
iCNS group (Supplementary Fig. 2). In seven of 18 cases
(38.8%), a negative ctDNA at the time of iCNS shifted to
positive when the patient had a systemic progression.
The number of metastatic sites (>2) at sample
collection was independently associated with a positive
ctDNA in multivariate analysis (odd ratio ¼ 3.4, 95%
confidence interval [CI]: 1.7–7.2, p ¼ 0.001) (data of
univariate analysis are depicted in Supplementary
Table 2). The median of MAF% was lower in iCNS
group (1% versus 2.7% noCNS and 9.4% cCNS, p <
0.0001) (Supplementary Fig. 3).Clinical Outcomes of Patients With Positive
ctDNA in the iCNS Group
In the iCNS group, median follow-up was 36.5
months (95% CI: 31–not reached [NR]). Subsequent
CNS progression occurred more frequently than extra-
CNS progression (79% versus 19%, p < 0.0001).
Positive ctDNA was more frequently associated with a
subsequent extra-CNS progression compared with
negative ctDNA (32% versus 7%, p ¼ 0.026), although
there were no differences in the clinical characteris-
tics of the two groups. In addition, we did not observe
any correlation between positive samples and the
burden of CNS disease (we considered multiple brain
metastases/leptomeningeal disease as high CNS tumor
burden) (p ¼ 0.93). The median time to the occur-
rence of extra-CNS progression was shorter in the
positive ctDNA group: 5.5 months (95% CI: 3.22–23)15%
48%
13%
9%
7%
12%
4%
2%
4%
cCNS
baseline. GA, genomic alteration.
Figure 3. Positive versus negative ctDNA. Results are represented as percentage from the total number of samples from each
group. Positive (green); negative (red).
388 Aldea et al Journal of Thoracic Oncology Vol. 15 No. 3versus NR in negative ctDNA (95% CI: 6.31–NR) (log-
rank 0.02).
Paired Plasma – CSF ctDNA
In the iCNS group, paired plasma–CSF liquid biopsies
were available for 12 patients (11 with leptomeningeal
progression and one with brain progression). Cytology in
CSF was positive in all cases with leptomeningeal
involvement. Samples were collected from patients with
known EGFRmutations (n¼ 11) and one patient with ALK
rearrangement. Plasma ctDNA was positive in six patients
(50%), versus 10 patients (83%) in whom tumor muta-
tions were detected in paired CSF samples (p ¼ 0.193).
Discussion
We evaluated the clinical utility of plasma ctDNA in
patients with oncogene-addicted NSCLC with isolated CNS
progression using a highly sensitive NGS assay. The
detection rate of 52% positive ctDNA in patients with
iCNS was significantly lower than in patients with noCNSTable 3. Prevalence of GA in Plasma ctDNA Samples
Type of GA iCNS
Overall (all) 52% (3
Actionable drivers (EGFR, ALK, BRAF, HER2, ROS1, MET) 37% (2
a 71% (2
Resistanceb (all EGFR, ALK, MET at progression) 6% (3/
a 13% (3
EGFR T790M in EGFR patients at progression 7% (2/
a 13% (2
Other 31% (2
apositive ctDNA only.
bEGFR T790M, EGFR C797S/G, EGFR G729S/V, EGFR L747P, ALK mutations, METor cCNS, 84% and 92%, respectively. However, 52%
positive ctDNA is relatively high compared with results
previously reported by De Mattos Arruda et al., in which
no GAs were detected in a limited number of patients
(n ¼ 7, including primary brain tumors).11 One possible
explanation is the cutoff of 2% MAF used in the study of
De Mattos Arruda et al., compared with a higher sensi-
tivity assay (as low as 0.02%) in our study.8,13,15 Our
results are in line with a study in patients with primary
brain tumors (N ¼ 419) in which the rate of positive
ctDNA was 51% with the Guardant360 assay.16 Another
study using the Guardant360 assay evaluated patients
with NSCLC with brain metastases and GAs were found in
75% of 12 cases, but the status of extra-CNS disease was
unknown.17 To our knowledge, our study is the largest
that evaluates isolated CNS progression in a cohort of
patients with various known baseline GAs: EGFR, ALK,
BRAF, HER2, KRAS, MET, PIK3CA, STK11, and TP53.
Isolated CNS progression mostly occurs in patients
with oncogenic drivers when TKIs are used withnoCNS cCNS p Value
3/64) 84% (108/128) 92% (101/110) <0.00001
2/60) 77% (79/102) 73% (67/92) <0.00001
2/31) 93% (79/85) 82% (68/83) 0.008
50) 45% (18/40) 44% (23/52) 0.00001
/23) 46% (18/39) 49% (23/47) 0.01
30) 48% (16/33) 50% (20/40) 0.0002
/16) 48% (16/33) 53% (20/38) 0.019
0/64) 65% (83/128) 68% (75/110) <0.00001
D1246N, EGFR, MET, and HER2 amplifications.
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supposed CNS tropism of some oncogenic drivers such
as ALK rearrangements. In our iCNS cohort, ALK rear-
rangement was detected in a higher frequency compared
with patients with systemic progression as most patients
were on crizotinib. This is consistent with other studies
that report a high CNS tropism for patients with ALK
rearrangements, reaching a risk of CNS disease of 58% at
3 years18 and 70% at progression during crizotinib
treatment.1,19,20
Importantly, plasma ctDNA detected a very low per-
centage of resistance mutations (6%) in patients with
iCNS, compared with more than 40% in patients with
systemic progression, for patients with alterations in
EGFR, ALK, or MET. This is in line with the results of
Zhang et al., in a prospective observational study of pa-
tients with EGFR-mutated NSCLC failing first-generation
TKI (n ¼ 307). EGFR T790M resistance mutation,
assessed by plasma ddPCR, was less frequently detected
in patients with progression limited to the brain (n ¼ 32)
than other sites (21.9% versus 72.3% respectively, p <
0.001).21 Interestingly, they reported that the resistance
mutation was less likely to be detected in patients with
disease limited to the chest (40.6%). The main hypoth-
esis is that the tumor burden drives the quantity of
ctDNA released into the blood. This is supported by the
correlation between the number of tumor sites and the
positivity of ctDNA in our study and others.22-24 This
might also explain why plasma positivity of iCNS patients
is related to higher number of patients with subsequent
extra-CNS progression in our study. It is likely that
ctDNA is released by infraradiologic lesions that subse-
quently become detectable. It has also been hypothe-
sized that reduced CNS drug penetration and low
exposure of first-generation TKI in CSF might cause a
different tumor selection in the CNS with the possibility
of retaining sensitizing mutations25-28 or with the
development of different resistance mechanisms.29 This
might explain the different prevalence of EGFR T790M
that has been reported within studies that compared CSF
with plasma.9,25,30
The reliability of GA detection by plasma ctDNA was
assessed also by the comparison between paired
plasma–CSF samples. There were more positive samples
in CSF compared with plasma (10 versus 6), although
not statistically significant, possibly because of the small
sample number (n ¼ 12). This was in line with other
studies that specifically compared CSF with plasma
ctDNA and found that CSF ctDNA had higher mutation
detection rates and higher MAF%, including patients
with NSCLC with CNS-unrestricted metastases (n ¼ 72),
EGFR (n ¼ 26) and ALK cohorts (n ¼ 11).3,9,11,30 More-
over, more unique mutations, including a higher number
of acquired resistance mutations, were identified in CSFthan in plasma.9 Indeed, in patients with low levels of
ctDNA, mutations may be more easily detected in CSF as
the tumor/normal DNA ratio is higher in CSF compared
with plasma. This is due to low levels of non–tumor
derived DNA in CSF.31,32
The main limitation of our study is the absence of a
comparison with the accepted standard tissue biopsy-
derived genomic profile, which for the iCNS subgroup
is not feasible to obtain. Other study limitations included
the retrospective collection of data (however, patients
were included in a prospective study at our institution),
the limited number of paired CSF samples, and the fact
that it was not possible to distinguish between ctDNA
and circulating free DNA in the absence of an identified
GA. Thus, correlations between positive/negative sam-
ples and ctDNA concentrations were not possible.
Another limitation is that InVisionFirst-Lung does not
identify all kind of ROS1 and ALK fusions, leaving rarer
partners or variants uncovered if present (e.g., EML4-
ALK V4, 5, 6, other than EML4 partner fusion). This
might result in false-negative liquid biopsies in the ALK/
ROS1 subgroup; however, it is unlikely that this would
considerably affect the results, because such variants
have a small prevalence in NSCLC.33
Alternative strategies should be explored in patients
with isolated CNS progression. CSF cell-free DNA anal-
ysis seems highly promising; however, its role in char-
acterizing patients with asymptomatic and with limited
brain lesions is less clear and might also be challenged
by low tumor-derived DNA levels in CSF. As in several
countries, first-line osimertinib is not yet reimbursed
and the presence of the EGFR T790M resistance mutation
remains mandatory for the use of osimertinib in second-
line treatment; therefore, better detection methods for
T790M or other treatment approaches are needed. In the
absence of resistance mutations after first- and second-
generation TKIs, an interesting strategy would also be
the investigation of plasma and CSF TKI concentrations,
which could guide intrapatient drug dosage escalations.Conclusions
Although tagged amplicon-based NGS has high
detection rates of GA in plasma ctDNA in patients with
NSCLC with extra-CNS disease, detection rate of GA
(52%) is lower in the subset of patients with iCNS dis-
ease. Complementary tests such as CSF cell-free DNA
assay may be useful. Further evidence would be bene-
ficial to understand the genomic landscape in patients
with NSCLC and iCNS.
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